Abstract: The present invention relates to methods for producing novel spinosyn derivatives which are substituted with a 1-hydroxy-ethyl radical in the C-21 position and to novel spinosyn derivatives of this type per se and to their use for producing novel spinosyns.

Abstract: Formulations consisting of phospholipid small unilamellar particles encapsulating polyene antifungal antibiotics and methods for using such compositions to treat systemic fungal infections are described. In a preferred embodiment, the particles are in the form of vesicles which comprise a polyene antifungal antibiotic, preferably amphotericin B and/or nystatin, egg phosphatidylcholine and cholesterol, preferably in the molar ratio of about 0.2 (AMB):2(PL):1(CHOL). These vesicles may also have an amine modified surface. The vesicles are suspended in a low isonic strength saccharide/tris solution at a pH of from about 6.0 to about 8.0 and may be administered to deliver the antifungal antibiotic to treat systemic fungal infections.

Abstract: Liquid dispersions are produced wherein amphotericin B, the methyl ester thereof, nystatin, trichomycin, primaricin and the like having a particle size of 10 .mu.m or less are dispersed in a suitable solvent such as physiologically acceptable saline. The dispersions are particularly useful for parenteral administration.

Abstract: Disclosed is a novel macrolide antibiotic, M 119, of the formula (A): ##STR1## wherein the substituent R designates either (a) or (d): (a) R: H(d) R: OH.The antibiotic M 119 has antimicrobial activity, particularly against Gram-positive bacteria, typical pathogenic bacteria falling under Gram-negative bacteria such as Haemophilus influenzae, and mycoplasmas, and is effective against infections induced by such bacteria.